[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350827-105":59,"doc-detail-350827-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","virus-like-particles-in-cancer-immunotherapy-bridging-human-and-veterinary-medicine-through-one-health","Virus-like particles in cancer immunotherapy - bridging human and veterinary medicine through one health","","Virus-like particles (VLPs) are engineered nanoplatforms that mimic viral structures, combining high immunogenicity, biocompatibility, and functional versatility for cancer immunotherapy. Although extensively studied in human oncology as nanovaccines and delivery systems for chemo-/immuno-therapeutics and genetic payloads, their use in veterinary oncology remains limited. This review synthesizes VLP design advances, mechanisms of VLP-induced antitumor immunity, and translational opportunities under the One Health framework, including comparative oncology with companion animals. It evaluates representative platforms’ translational readiness and proposes a roadmap for manufacturing standardization, biomarker development, validation, precision engineering, and emerging technologies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/virus-like-particles-in-cancer-immunotherapy-bridging-human-and-veterinary-medicine-through-one-health/350827/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/virus-like-particles-in-cancer-immunotherapy-bridging-human-and-veterinary-medicine-through-one-health/350827.png","ImageObject",300,407,{"name":92,"@type":93},"MrHarris58","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What are virus-like particles (VLPs) and why are they useful for cancer immunotherapy?","Question",{"text":113,"@type":114},"VLPs mimic viral structures without genetic material, making them non-infectious. Their size, geometry, and surface repetitiveness support strong immunogenicity and efficient immune activation.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How do engineered VLPs trigger antitumor immunity?",{"text":118,"@type":114},"VLPs can activate dendritic cells and innate immune sensors, then bridge to adaptive immunity by driving cross-presentation of tumor antigens and promoting tumor-specific cytotoxic T lymphocytes.",{"name":120,"@type":111,"acceptedAnswer":121},"Why does the review emphasize One Health and companion animals in translational research?",{"text":122,"@type":114},"Companion animals with spontaneous tumors provide immunocompetent translational models. Comparative oncology shows parallels in oncogenic pathways, immune landscapes, and therapeutic responses, supporting shared development and biomarker work across species.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350827,1790472025,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},687212988360,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Zhu et al. Journal of Nanobiotechnology (2026) 24:867 Journal of Nanobiotechnology  \n[https://doi.org/10.1186/s12951-026-04703-9](https://doi.org/10.1186/s12951-026-04703-9)  \nREVIEW Open Access  \nVirus-like particles in cancer immunotherapy: bridging human and veterinary medicine through one health  \nYingqi Zhu1†, Zhuangli Bi1,2†, Zichen Zhang1,2, Miao Zhang1, Qingqing Du1,2, Mingxing Hu1,2, Ting Zhou1,2, Yiming Fan1, Shu Zhang3*, Guijun Wang2* and Guangqing Liu 1*  \nAbstract  \nVirus-like particles (VLPs) are engineered nanoplatforms that mimic viral structures, offering high immunogenicity, biocompatibility, and functional versatility for cancer immunotherapy. While widely explored in human oncology as nanovaccines and targeted delivery systems for chemo-/immuno-therapeutics and genetic payloads (e. g., mRNA, siRNA, and CRISPR/Cas systems), their potential in veterinary oncology remains underexploited. This review synthesizes recent advances in VLP design, including scaffold engineering, antigen display, cargo encapsulation, and surface functionalization, and discusses the mechanistic basis of VLP-induced antitumor immunity, encompassing dendritic cell activation, adaptive immune amplification, and tumor microenvironment remodeling. Importantly, we highlight the emerging role of companion animals with spontaneous tumors—such as lymphoma, melanoma, and mammary carcinoma—as immunocompetent translational models within the One Health framework. Comparative oncology reveals striking parallels in oncogenic pathways, immune landscapes, and therapeutic responses, supporting the use of canine and feline cancers as biologically relevant intermediates between murine studies and human clinical trials. We provide an evidence-based assessment of representative VLP platforms, evaluate their translational readiness, and examine cross-species opportunities for shared  \ntarget development, biomarker discovery, and regulatory convergence, while also addressing species-specific biological and technical limitations. Finally, we propose a forward-looking roadmap that prioritizes manufacturing standardization, biomarker development, comparative validation, precision engineering, and emerging technologies such as AI-guided design and tumor-on-chip systems. Collectively, we position One Health as an operational strategy to accelerate the bidirectional translation of VLP-based immunotherapies for both human and veterinary cancer patients.  \n†Yingqi Zhu and Zhuangli Bi contributed equally to this work.  \n*Correspondence: Shu Zhang [superdrzhang@yeah.net](superdrzhang@yeah.net)[ ](superdrzhang@yeah.net)Guijun Wang [wgj2018@ahau.edu.cn](wgj2018@ahau.edu.cn)[ ](wgj2018@ahau.edu.cn)Guangqing Liu [liugq@shvri.ac.cn](liugq@shvri.ac.cn)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nZhu et al. Journal of Na","cbCaiqxJPDV1ZCaz","https://ap.wps.com/l/cbCaiqxJPDV1ZCaz","pdf",3377988,29,"English","# Abstract\n## Introduction\n## Virus-like particles (VLPs)\n## Translational opportunities under One Health","[{\"question\":\"What are virus-like particles (VLPs) and why are they useful for cancer immunotherapy?\",\"answer\":\"VLPs mimic viral structures without genetic material, making them non-infectious. Their size, geometry, and surface repetitiveness support strong immunogenicity and efficient immune activation.\"},{\"question\":\"How do engineered VLPs trigger antitumor immunity?\",\"answer\":\"VLPs can activate dendritic cells and innate immune sensors, then bridge to adaptive immunity by driving cross-presentation of tumor antigens and promoting tumor-specific cytotoxic T lymphocytes.\"},{\"question\":\"Why does the review emphasize One Health and companion animals in translational research?\",\"answer\":\"Companion animals with spontaneous tumors provide immunocompetent translational models. Comparative oncology shows parallels in oncogenic pathways, immune landscapes, and therapeutic responses, supporting shared development and biomarker work across species.\"}]","Virus-like particles in cancer immunotherapy - bridging human and veterinary medicine through one health | PDF",1790091344,73,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/617d577061ab53e2c096bab72f4e59eb.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9f366cdbe625538329e26442d386d0e.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc645952d9de94bf18b053b5892c6226.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4185ec7b5605a9f3a78b16b6eb01829.webp",980,1306]